This is particularly important when strategies targeting HGPS at the molecular level are designed, and is also one of the prerequisites for effective implementation of nucleic acid therapy in HGPS patients. The gene discussed is ZMPSTE24; the disease is Hutchinson-Gilford progeria syndrome.